Lipid and apoprotein composition of HDL in partial or complete CETP deficiency

Current Vascular Pharmacology

Volumn 10, Issue 4, 2012, Pages 422-431

  Niesor, Eric J ^a   von der Mark, Elisabeth ^a   Calabresi, Laura ^b   Averna, Maurizio ^c   Cefalù, Angelo B ^c   Tarugi, Patrizia ^d   Nilsson, Peter ^e   Dernick, Gregor ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF PALERMO   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e LUND UNIVERSITY   (Sweden)

Author keywords

Cholesteryl ester transfer protein; Dalcetrapib; High density lipoprotein; Reverse phase protein array; Scavenger receptor class B1; Size exclusion chromatography; Torcetrapib

Indexed keywords

ANACETRAPIB; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN C1; APOLIPOPROTEIN C3; APOPROTEIN; CHOLESTEROL ESTER TRANSFER PROTEIN; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; TORCETRAPIB;

ARTICLE; CAUCASIAN; CHOLESTERYL ESTER TRANSFER PROTEIN DEFICIENCY; CODON; ENZYME ACTIVITY; EXON; GEL PERMEATION CHROMATOGRAPHY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LIPOPROTEIN DEFICIENCY; POINT MUTATION;

ANIMALS; APOLIPOPROTEINS; CHOLESTEROL ESTER TRANSFER PROTEINS; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERCHOLESTEROLEMIA; LIPID METABOLISM; LIPIDS; LIPOPROTEINS, HDL;

EID: 84861673540     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112800812683     Document Type: Article

References (56)

1. Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis 1988; 8: 737-41.
2. Rye KA, Clay MA, Barter PJ. Remodeling of high density lipoproteins by plasma factors. Atherosclerosis 1999; 145: 227-38.
3. Niesor EJ, Magg C, Ogawa N, et al. Modulating cholesteryl ester transfer protein activity maintains efficient pre--HDL formation and increases reverse cholesterol transport. J Lipid Res 2010; 51: 3443-54.
4. Camps J, Marsillach J, Joven J. The paraoxonases: role in human diseases and methodological difficulties in measurement. Crit Rev Clin Lab Sci 2009; 46: 83-106.
5. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011; 8: 222-32.
6. Knoblauch H, Bauerfeind A, Toliat MR, et al. Haplotypes and SNPs in 13 lipid-relevant genes explain most of the genetic variance in high-density lipoprotein and low-density lipoprotein cholesterol. Hum Mol Genet 2004; 13: 993-1004.
7. Brown ML, Inazu A, Hesler CB, et al. Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989; 342: 448-51.
8. Yamashita S, Matsuzawa Y, Okazaki M, et al. Small polydisperse low density lipoproteins in familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Atherosclerosis 1988; 70: 7-12.
9. Arai T, Tsukada T, Murase T, et al. Particle size analysis of high density lipoproteins in patients with genetic cholesteryl ester transfer protein deficiency. Clin Chim Acta 2000; 301: 103-17.
10. Bisgaier CL, Siebenkas MV, Brown ML, et al. Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res 1991; 32: 21-33.
11. Lagrost L, Gambert P, Dangremont V, Athias A, Lallemant C. Role of cholesteryl ester transfer protein (CETP) in the HDL conversion process as evidenced by using anti-CETP monoclonal antibodies. J Lipid Res 1990; 31: 1569-75.
12. Barter PJ. Hugh Sinclair Lecture: The regulation and remodeling of HDL by plasma factors. Atheroscler Suppl 2002; 3: 39-47.
13. Rye KA, Barter PJ. Formation and metabolism of prebetamigrating, lipid-poor apolipoprotein A-I. Arterioscler Thromb Vasc Biol 2004; 24: 421-8.
14. Yamashita S, Hirano K, Sakai N, Matsuzawa Y. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochim Biophys Acta 2000; 1529: 257-75.
15. Vaisar T, Pennathur S, Green PS, et al. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007; 117: 746-56.
16. Cohn JS, Tremblay M, Amiot M, et al. Plasma concentration of apolipoprotein E in intermediate-sized remnant-like lipoproteins in normolipidemic and hyperlipidemic subjects. Arterioscler Thromb Vasc Biol 1996; 16: 149-59.
17. Davidsson P, Hulthe J, Fagerberg B, Camejo G. Proteomics of apolipoproteins and associated proteins from plasma high-density lipoproteins. Arterioscler Thromb Vasc Biol 2010; 30: 156-63.
18. Okamoto H, Yonemori F, Wakitani K, Minowa T, Maeda K, Shinkai H. A cholesteryl ester transfer protein inhibitor attenuates atherosclerosis in rabbits. Nature 2000 13; 406: 203-7.
19. Ranalletta M, Bierilo KK, Chen Y, et al. Biochemical characterization of cholesteryl ester transfer protein inhibitors. J Lipid Res 2010; 51: 2739-52.
20. Schwartz GG, Olsson AG, Ballantyne CM, et al. Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896-901. e3.
21. Mao D, Kai G, Gaofu Q, et al. Intramuscular immunization with a DNA vaccine encoding a 26-amino acid CETP epitope displayed by HBc protein and containing CpG DNA inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 2006; 24: 4942-50.
22. Cefalù AB, Noto D, Magnolo L, et al. Novel mutations of CETP gene in Italian subjects with hyperalphalipoproteinemia. Atherosclerosis 2009; 204: 202-7.
23. Calabresi L, Nilsson P, Pinotti E, et al. A novel homozygous mutation in CETP gene as a cause of CETP deficiency in a Caucasian kindred. Atherosclerosis 2009; 205: 506-11.
24. Morton RE, Greene DJ. Regulation of lipid transfer between lipoproteins by an endogenous plasma protein: selective inhibition among lipoprotein classes. J Lipid Res 1994; 35: 836-47.
25. Paromov VM, Morton RE. Lipid transfer inhibitor protein defines the participation of high density lipoprotein subfractions in lipid transfer reactions mediated by cholesterol ester transfer protein (CETP). J Biol Chem 2003; 278: 40859-66.
26. Hennes U, Gross W, Edelmann A. Changes in lipoprotein patterns in hamsters under different metabolic states analyzed following separation by micropreparative chromatography on SMART System from multiple micro plasma samplings. Science Tools 1992; 36: 10-12.
27. Innis-Whitehouse W, Li X, Brown WV, Le NA. An efficient chromatographic system for lipoprotein fractionation using whole plasma. J Lipid Res 1998; 39: 679-90.
28. Dernick G, Obermüller S, Mangold C, et al. Multidimensional profiling of plasma lipoproteins by size exclusion chromatography followed by reverse phase protein arrays. J Lipid Res 2011; 52: 2323-31.
29. Fattinger C, Dernick G. High-density plates, microarrays, microfluidics. In exploiting chemical diversity for drug discovery. Bartlet PA, Entzeroth M, Eds. The Royal Society of Chemistry, Cambridge, UK 2006; pp: 201-32.
30. Shinkai H. Cholesteryl ester transfer protein inhibitors as highdensity lipoprotein raising agents. Expert Opin Ther Pat 2009; 19: 1229-37.
31. Clark RW, Ruggeri RB, Cunningham D, et al. Description of the torcetrapib series of cholesteryl ester transfer protein inhibitors, including mechanism of action. J Lipid Res 2006; 47: 537-52.
32. Clark RW. Raising high-density lipoprotein with cholesteryl ester transfer protein inhibitors. Curr Opin Pharmacol 2006; 6: 162-8.
33. Stein EA, Stroes ES, Steiner G, et al. Safety and tolerability of dalcetrapib. Am J Cardiol 2009; 104: 82-91.
34. Hirayama S, Kobayashi J, Taira K, et al. Marked elevation in serum apolipoprotein E in a case of heterozygous cholesteryl ester transfer protein deficiency. Clin Chim Acta 2000; 301: 55-64.
35. Keidar S, Ostlund RE, Jr., Schonfeld G. Apolipoprotein E-rich HDL in patients with homozygous familial hypercholesterolemia. Atherosclerosis 1990; 84: 155-63.
36. Deckelbaum RJ, Eisenberg S, Oschry Y, et al. Abnormal high density lipoproteins of abetalipoproteinemia: relevance to normal HDL metabolism. J Lipid Res 1982; 23: 1274-82.
37. Yamashita S, Sprecher DL, Sakai N, et al. Accumulation of apolipoprotein E-rich high density lipoproteins in hyperalphalipoproteinemic human subjects with plasma cholesteryl ester transfer protein deficiency. J Clin Invest 1990; 86: 688-95.
38. Asztalos BF, Horvath KV, Kajinami K, et al. Apolipoprotein composition of HDL in cholesteryl ester transfer protein deficiency. J Lipid Res 2004; 45: 448-55.
39. Collet X, Tall AR, Serajuddin H, et al. Remodeling of HDL by CETP in vivo and by CETP and hepatic lipase in vitro results in enhanced uptake of HDL CE by cells expressing scavenger receptor B-I. J Lipid Res 1999; 40: 1185-93.
40. Gauthier A, Lau P, Zha X, et al. Cholesteryl ester transfer protein directly mediates selective uptake of high density lipoprotein cholesteryl esters by the liver. Arterioscler Thromb Vasc Biol 2005; 25: 2177-84.
41. Zhou H, Li Z, Silver DL, Jiang XC. Cholesteryl ester transfer protein (CETP) expression enhances HDL cholesteryl ester liver delivery, which is independent of scavenger receptor BI, LDL receptor related protein and possibly LDL receptor. Biochim Biophys Acta 2006; 1761: 1482-8.
42. Tall A. Plasma lipid transfer proteins. Annu Rev Biochem 1995; 64: 235-57.
43. Rosenson RS, Brewer HB Jr, Chapman MJ, et al. HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem 2011; 57: 392-410.
44. Ishigami M, Yamashita S, Sakai N, et al. Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem 1994; 116: 257-62.
45. Plengpanich W, Le Goff W, Poolsuk S, Julia Z, Guerin M, Khovidhunkit W. CETP deficiency due to a novel mutation in the CETP gene promoter and its effect on cholesterol efflux and selective uptake into hepatocytes. Atherosclerosis 2011; 216: 370-3.
46. Matsuura F, Wang N, Chen W, et al. HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE-and ABCG1-dependent pathway. J Clin Invest 2006; 116: 1435-42.
47. Miwa K, Inazu A, Kawashiri M, et al. Cholesterol efflux from J774 macrophages and Fu5AH hepatoma cells to serum is preserved in CETP-deficient patients. Clin Chim Acta 2009; 402: 19-24.
48. Niesor EJ. Different effects of compounds decreasing CETP activity on lipoprotein metabolism. Curr Opin Lipidol 2011; 22: 288-95.
49. Wolk R, Chen D, Clark RW, et al. Pharmacokinetic, pharmacodynamic, and safety profile of a new cholesteryl ester transfer protein inhibitor in healthy human subjects. Clin Pharmacol Ther 2009; 86: 430-7.
50. Evans GF, Bensch WR, Apelgren LD, et al. Inhibition of cholesteryl ester transfer protein in normocholesterolemic and hypercholesterolemic hamsters: effects on HDL subspecies, quantity, and apolipoprotein distribution. J Lipid Res 1994; 35: 1634-45.
51. Clark RW, Sutfin TA, Ruggeri RB, et al. Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 2004; 24: 490-7.
52. Rigotti A, Trigatti BL, Penman M, Rayburn H, Herz J, Krieger M. A targeted mutation in the murine gene encoding the high density lipoprotein (HDL) receptor scavenger receptor class B type I reveals its key role in HDL metabolism. Proc Natl Acad Sci USA 1997; 94: 12610-5.
53. El-Bouhassani M, Gilibert S, Moreau M, et al. Cholesteryl ester transfer protein expression partially attenuates the adverse effects of SR-BI receptor deficiency on cholesterol metabolism and atherosclerosis. J Biol Chem 2011; 286: 17227-38.
54. Kunitake ST, Mendel CM, Hennessy LK. Interconversion between apolipoprotein A-I-containing lipoproteins of pre-beta and alpha electrophoretic mobilities. J Lipid Res 1992; 33: 1807-16.
55. Hine D, Mackness B, Mackness M. Cholesteryl-ester transfer protein enhances the ability of high-density lipoprotein to inhibit lowdensity lipoprotein oxidation. IUBMB Life 2011 Aug 3. doi: 10.1002/iub.508 [E-pub ahead of print].
56. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: focus on antioxidative activities. Curr Opin Lipidol 2010; 21: 312-8.